Pyxis Oncology Inc

PYXSNASDAQ · USD
3.22USD0.00 (-4.03%)
1210

Pyxis Oncology Inc (PYXS) Wheel Strategy

PYXS wheel strategy scan found 1 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 60.8%.

Read more

Running a PYXS wheel strategy lets you generate consistent premium income on Pyxis Oncology Inc while setting your own entry and exit prices on the underlying. Pyxis Oncology Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own PYXS, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best PYXS wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on PYXS, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable PYXS wheel from a losing one.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the PYXS wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your PYXS wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 16, 20262.50$0.05$0.10-0.152420%73.4%60.8%202

As of September 23, 2026

Run the Wheel on PYXS With Confidence

Find the best PYXS wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial